DarioHealth stock gained 3.79 percent as Aon backs savings

Published on 10/07/2026 at 07:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DarioHealth stock reflects Aon estimates of 2.5% to 7.2% annual savings dated October 6, 2026. Q2 EPS was USD -0.85 versus USD -1.22 consensus.

DRIO, US23725P3082, Illustration mit AI erstellt.

DarioHealth Corp. (ISIN US23725P3082) was last at USD 6.02 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, up 3.79 percent from the prior close. The move followed an Aon review that supported measurable cost savings from Dario's digital health platform, according to PR Newswire on October 6, 2026.

Aon puts savings in numbers

The review estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population. For 20,000 covered lives, the analysis cited annual savings of USD 3.8 million to USD 10.8 million, while a component study found USD 5,077 in annual savings per Dario user with type 2 diabetes.

The review covered 17 studies identified by Dario and included cardiometabolic, musculoskeletal and behavioral health evidence. It also identified 23.5% fewer inpatient discharges per Dario user with type 2 diabetes than among matched non-users, although the release said Aon did not independently audit the underlying studies or data.

Q2 revenue missed estimates

The commercial case faces a recent financial counterweight. Dario reported second-quarter 2026 revenue of USD 5.18 million against USD 5.92 million consensus, a USD 0.74 million shortfall, while adjusted earnings per share came in at USD -0.85 versus USD -1.22 expected, according to MarketBeat in its Q2 2026 results coverage.

Dario's Q2 revenue was also below the USD 5.584 million recorded in the first quarter of 2026, while the quarterly loss per share was narrower than the consensus estimate. The contrast matters because the Aon findings strengthen the payer value proposition, but revenue conversion remains the operational test for the stock.

Consensus target exceeds USD 13

Investing.com lists a Strong Buy consensus from 5 analysts, an average 12-month price target of USD 13.60, a high target of USD 28 and a low target of USD 8.00. The average target lies 125.91 percent above the USD 6.02 Nasdaq price, according to Investing.com.

The share price remains 63.62 percent below its 52-week high of USD 16.55 and sits at the 52-week low of USD 5.80 only after the October 6 move. That wide range leaves the market balancing the savings evidence against the company's reported revenue pace and cash use.

DarioHealth stock stays below USD 7

DarioHealth stock was last at USD 6.02 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The market capitalization was USD 44.0 million and volume was 7,633 shares for that session.